Relay Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(261,704) | $(258,478) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock compensation expense | 76,504 | 66,764 |
| Depreciation expense | 4,130 | 3,894 |
| Net amortization of premiums and discounts on investments | (10,134) | (7,094) |
| Change in fair value of contingent consideration liability | (13,206) | (4,355) |
| Changes in assets and liabilities: | ||
| Accounts receivable | — | 95 |
| Contract asset | — | 4,913 |
| Prepaid expenses and other current assets | (5,503) | (5,603) |
| Operating lease assets and liabilities, net | 961 | 1,159 |
| Accounts payable | (993) | 2,980 |
| Accrued expenses and other liabilities | 18,706 | (15,427) |
| Deferred revenue | — | 24 |
| Net cash used in operating activities | (191,239) | (211,128) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,018) | (4,008) |
| Purchases of investments | (575,553) | (248,727) |
| Proceeds from maturities of investments | 507,490 | 450,691 |
| Net cash (used in) provided by investing activities | (70,081) | 197,956 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock through Private Placement, net | 29,803 | — |
| Proceeds from issuance of common stock via at-the-market offerings, net | 17,932 | 9,363 |
| Proceeds from issuance of common stock through follow-on offering, net | 218,157 | — |
| Proceeds from issuance of common stock upon exercise of stock options | 2,332 | 1,845 |
| Proceeds from issuance of common stock via employee stock purchase plan | 1,129 | 1,627 |
| Net cash provided by financing activities | 269,353 | 12,835 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 8,033 | (337) |
| Cash, cash equivalents, and restricted cash at beginning of period | 146,443 | 154,372 |
| Cash, cash equivalents, and restricted cash at end of period | $154,476 | $154,035 |
| Supplemental disclosure of non-cash activities: | ||
| Periodic change to additions of property and equipment in current liabilities | $(1,579) | $(1,047) |
Reconciliation of Cash, Cash Equivalents, and Restricted Cash from Balance Sheets to Statement of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| (in thousands) | ||
| Cash and cash equivalents | $152,357 | $151,328 |
| Restricted cash | 2,119 | 2,707 |
| Cash, cash equivalents, and restricted cash per statements of cash flows | $154,476 | $154,035 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.